Mirna expects to price IPO of 6.25 million shares at $7.00 per share

Citigroup, Leerink, Oppenheimer and Cantor Fitzgerald are bookrunners

By Devika Patel

Knoxville, Tenn., Sept. 30 – Mirna Therapeutics, Inc. will sell 6.25 million common shares in its initial public offering with a 30-day greenshoe of 937,500 additional shares, according to a free writing prospectus filed Wednesday with the Securities and Exchange Commission. The deal was announced on Aug. 24.

The shares will be sold at an expected price of $7.00 per share.

Citigroup Global Markets Inc., Leerink Partners LLC, Oppenheimer & Co. Inc. and Cantor Fitzgerald & Co. are the bookrunners.

Proceeds will be used for clinical expenses, preclinical studies, working capital and other general corporate purposes.

Mirna is a clinical-stage biopharmaceutical company based in Austin, Texas. The company has applied to list its stock on the Nasdaq Global Market under the symbol “MIRN.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.